Track topics on Twitter Track topics that are important to you
Celgene has ended its option to acquire Sutro Biopharma in return for gaining full global rights to a second Sutro preclinical program, and outside-U.S. rights to two others, in a reworking of the companies’ immuno-oncology collaboration whose value was not disclosed. A revised agreement allows Celgene to acquire worldwide rights to the second Sutro preclinical program to reach investigational new drug (IND) status, in return for unspecified payments to Sutro—while retaining such rights to the first preclinical program that advances to an IND, as called for under a 2014 expansion of the collaboration. That first preclinical program is an antibody drug conjugate (ADC) program designed to fight multiple myeloma by targeting B-Cell maturation antigen (BCMA), a program disclosed earlier by Celgene. The other three preclinical programs are intended to develop immuno-oncology bispecific monoclonal antibodies against undisclosed targets. Celgene also secured ex-U.S. rights to the next two ...NEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...